Lamin A/C antibody | knockout validation | Cell signalling Technology
DOI
//dx.doi.org/10.13070/ko.en.6.1791
Date
2016-11-08

This is a knockout-validated antibody summary, based on the publication "Evidence that proteasome-dependent degradation of the retinoblastoma protein in cells lacking A-type lamins occurs independently of gankyrin and MDM2", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Lamin A/C antibody | knockout validation | Cell signalling Technology figure 1
Figure 1. Western blot of WT and Lmna -/- fibroblast cell lines and of NIH3T3 cells treated with siRNA targeting the Lmna gene. Blot probed with anti-Lamin A/C antibody. Actin serves as a loading control. From [1].
Antibody information

Rabbit polyclonal

Company: Cell Signaling Technology

Antibody: Lamin A/C

Catalog number: 2032

Summary: Rabbit polyclonal antibody raised against a synthetic peptide corresponding to the sequence surrounding Asp230 of human lamin A.

Detects lamin A and lamin C.

Supplier recommended for WB and IHC.

Reacts with lamin A/C from human, mouse and rat.

Validation Method

Western blot

Sample

Wild-type and Lmna -/- immortalised fibroblast cell lines total cell extracts.

Detection

Detection reagent not stated. Pixel counting using NIH Image.

Disclaimer

If the antibody described in this summary is a polyclonal antibody, since polyclonal antibodies are of limited quantity, please inquire the supplier whether any current polyclonal antibody with the same catalog number is exactly the same as the one described in this summary. Sometimes, different bleeds or different animals are used, usually with a different lot number. In such cases, the result in this summary may not apply to the new antibody with the same catalog number.

References
  1. Nitta R, Smith C, Kennedy B. Evidence that proteasome-dependent degradation of the retinoblastoma protein in cells lacking A-type lamins occurs independently of gankyrin and MDM2. PLoS ONE. 2007;2:e963 pubmed